Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $25.11 million. The enterprise value is $15.85 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 11.21 million shares outstanding. The number of shares has increased by 1.26% in one year.
| Current Share Class | 11.21M |
| Shares Outstanding | 11.21M |
| Shares Change (YoY) | +1.26% |
| Shares Change (QoQ) | +4.47% |
| Owned by Insiders (%) | 3.26% |
| Owned by Institutions (%) | 11.58% |
| Float | 8.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.24 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.40 |
| Quick Ratio | 2.25 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -123.51% and return on invested capital (ROIC) is -80.13%.
| Return on Equity (ROE) | -123.51% |
| Return on Assets (ROA) | -61.39% |
| Return on Invested Capital (ROIC) | -80.13% |
| Return on Capital Employed (ROCE) | -275.14% |
| Weighted Average Cost of Capital (WACC) | 13.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.60% in the last 52 weeks. The beta is 1.75, so Lantern Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | -37.60% |
| 50-Day Moving Average | 2.34 |
| 200-Day Moving Average | 3.45 |
| Relative Strength Index (RSI) | 48.62 |
| Average Volume (20 Days) | 1,113,130 |
Short Selling Information
The latest short interest is 1.74 million, so 15.53% of the outstanding shares have been sold short.
| Short Interest | 1.74M |
| Short Previous Month | 2.19M |
| Short % of Shares Out | 15.53% |
| Short % of Float | 20.40% |
| Short Ratio (days to cover) | 1.21 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.98M |
| Pretax Income | -17.12M |
| Net Income | -17.12M |
| EBITDA | -17.96M |
| EBIT | -17.98M |
| Earnings Per Share (EPS) | -$1.57 |
Full Income StatementBalance Sheet
The company has $10.12 million in cash and $78,539 in debt, with a net cash position of $10.04 million or $0.90 per share.
| Cash & Cash Equivalents | 10.12M |
| Total Debt | 78,539 |
| Net Cash | 10.04M |
| Net Cash Per Share | $0.90 |
| Equity (Book Value) | 6.53M |
| Book Value Per Share | 0.58 |
| Working Capital | 6.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.68 million and capital expenditures -$1,715, giving a free cash flow of -$15.68 million.
| Operating Cash Flow | -15.68M |
| Capital Expenditures | -1,715 |
| Depreciation & Amortization | 17,280 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.68M |
| FCF Per Share | -$1.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
